Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis

Abstract Despite limited efficacy of immunotherapy for advanced non-small-cell lung cancer (NSCLC) with driver mutations, whether neoadjuvant immunotherapy could be clinically valuable in those patients warrants further investigation. We utilized 40 oncogene-mutant NSCLC treated with induction immun...

Полное описание

Библиографические подробности

Главные авторы:	Chao Zhang, Hua-Fei Chen, Shi Yan, Lin Wu, Li-Xu Yan, Xiao-Long Yan, Dong-Sheng Yue, Chun-Wei Xu, Min Zheng, Ji-Sheng Li, Si-Yang Liu, Ling-Ling Yang, Ben-Yuan Jiang, Qiu-Xiang Ou, Zhen-Bin Qiu, Yang Shao, Yi-Long Wu, Wen-Zhao Zhong
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Nature Portfolio 2022-09-01
Серии:	npj Precision Oncology
Online-ссылка:	https://doi.org/10.1038/s41698-022-00301-8
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!